FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
Express Mail Label Number	Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AUWERX ET AL.

APPLICATION NO: 10/568,637 FILED: FEBRUARY 16, 2006

FOR: INHIBITION OF S6 KINASE ACTIVITY FOR THE TREATMENT OF

INSULIN RESISTANCE

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is in response to the Restriction Requirement dated June 23, 2008 having a shortened statutory **three**-month period. Although Applicants believe that no extension of time is necessary, the Office is authorized to charge Deposit Account No. **50-4409** for any extension of time or other required fee for consideration of the instant response.

In Response to the Restriction Requirement mailed June 23, 2008, Applicant hereby elects Group IV, claims 11-18, drawn to methods for treating insulin resistance using an S6 kinase inhibitor. In response to the species election requirement, Applicants elect inhibitors of S6 kinase activity. Applicant elects without traverse.

Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139

(617) 871-3105

late Alauandar

John Alexander Attorney for Applicants Reg. No. 48,399

Respectfully submitted,